Drug lookup | Fillwise

AG-Pantoprazole Sodium · DIN 02481588 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

AG-Pantoprazole Sodium · DIN 02481588 Manufacturer: Angita Pharma Inc.; listing date 2021-01-29 Health Canada: Marketed since 2018-12-27 · brand AG-PANTOPRAZOLE SODIUM · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40 MG · company Angita pharma inc. · schedule Prescription

Check this DIN again · Health Canada product record

AG-Pantoprazole Sodium: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97204 · Verify on the e-Formulary ↗ (DIN 02481588)

Source record

DIN 02481588: AG-Pantoprazole Sodium Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id ANG Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481588 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97204

Interchangeable products

Apo-Pantoprazole · DIN 02292920 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481588

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Pantoprazole · DIN 02292920 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Pantoprazole · DIN 02292920 Manufacturer: Apotex Inc.; listing date 2008-05-16 Health Canada: Marketed since 2008-03-05 · brand APO-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Pantoprazole: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77827 · Verify on the e-Formulary ↗ (DIN 02292920)

Source record

DIN 02292920: Apo-Pantoprazole Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id APX Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292920 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77827

Interchangeable products

AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: shortage reported ended 2026-08-27 (report last updated 2026-08-27); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292920

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Pantoprazole · DIN 02415208 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Pantoprazole · DIN 02415208 Manufacturer: Auro Pharma Inc.; listing date 2014-05-29 Health Canada: Marketed since 2016-02-06 · brand AURO-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Pantoprazole: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89982 · Verify on the e-Formulary ↗ (DIN 02415208)

Source record

DIN 02415208: Auro-Pantoprazole Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id AUR Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02415208 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89982

Interchangeable products

AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Apo-Pantoprazole · DIN 02292920 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: resolved shortage (ended 2018-09-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02415208

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Pantoprazole · DIN 02445867 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-19

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Bio-Pantoprazole · DIN 02445867 Manufacturer: Biomed Pharma; listing date 2026-07-31 Health Canada: Marketed since 2024-03-13 · brand BIO-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Biomed pharma · schedule Prescription

Check this DIN again · Health Canada product record

Bio-Pantoprazole: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93114 · Verify on the e-Formulary ↗ (DIN 02445867)

Source record

DIN 02445867: Bio-Pantoprazole Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id BMP Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02445867 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93114

Interchangeable products

AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Apo-Pantoprazole · DIN 02292920 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: resolved shortage (ended 2018-11-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02445867

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Pantoprazole Sodium · DIN 02392623 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp Pantoprazole Sodium · DIN 02392623 Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30 Health Canada: Marketed since 2021-03-18 · brand JAMP PANTOPRAZOLE SODIUM · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Pantoprazole Sodium: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87788 · Verify on the e-Formulary ↗ (DIN 02392623)

Source record

DIN 02392623: Jamp Pantoprazole Sodium Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id JPC Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02392623 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87788

Interchangeable products

AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Apo-Pantoprazole · DIN 02292920 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: resolved shortage (ended 2025-05-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392623

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Pantoprazole · DIN 02357054 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Pantoprazole · DIN 02357054 Manufacturer: Jamp Pharma Corporation; listing date 2014-02-27 Health Canada: Marketed since 2020-06-15 · brand JAMP-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Pantoprazole: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84215 · Verify on the e-Formulary ↗ (DIN 02357054)

Source record

DIN 02357054: Jamp-Pantoprazole Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id JPC Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357054 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84215

Interchangeable products

AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Apo-Pantoprazole · DIN 02292920 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02357054

Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Pantoprazole · DIN 02467372 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

M-Pantoprazole · DIN 02467372 Manufacturer: Mantra Pharma Inc.; listing date 2019-03-28 Health Canada: Marketed since 2024-08-21 · brand M-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40 MG · company Mantra pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

M-Pantoprazole: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95575 · Verify on the e-Formulary ↗ (DIN 02467372)

Source record

DIN 02467372: M-Pantoprazole Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id MAT Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467372 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95575

Interchangeable products

AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Apo-Pantoprazole · DIN 02292920 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: resolved shortage (ended 2021-09-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02467372

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Pantoprazole · DIN 02416565 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Pantoprazole · DIN 02416565 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-04-01 Health Canada: Marketed since 2014-07-18 · brand MAR-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mar-Pantoprazole: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90116 · Verify on the e-Formulary ↗ (DIN 02416565)

Source record

DIN 02416565: Mar-Pantoprazole Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id MAR Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02416565 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90116

Interchangeable products

AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Apo-Pantoprazole · DIN 02292920 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: resolved shortage (ended 2020-06-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416565

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Pantoprazole · DIN 02417448 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Pantoprazole · DIN 02417448 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-04-30 Health Canada: Marketed since 2014-01-16 · brand MINT-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Pantoprazole: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90206 · Verify on the e-Formulary ↗ (DIN 02417448)

Source record

DIN 02417448: Mint-Pantoprazole Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id MIN Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02417448 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90206

Interchangeable products

AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Apo-Pantoprazole · DIN 02292920 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: resolved shortage (ended 2019-11-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02417448

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Pantoprazole · DIN 02471825 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Pantoprazole · DIN 02471825 Manufacturer: Nora Pharma; listing date 2020-10-30 Health Canada: Marketed since 2024-05-27 · brand NRA-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Pantoprazole: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96103 · Verify on the e-Formulary ↗ (DIN 02471825)

Source record

DIN 02471825: NRA-Pantoprazole Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id NRA Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471825 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96103

Interchangeable products

AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Apo-Pantoprazole · DIN 02292920 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 PMS-Pantoprazole · DIN 02307871 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471825

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Pantoprazole · DIN 02307871 · 40mg · enteric-coated tablet

Limited Use — Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 293, 295, 297, 401, 402 required

Write on scriptLU code 293, 295, 297, 401, 402 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 293, 295, 297, 401, 402

Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 295 H. pylori-positive Peptic Ulcers For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy. Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment). Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Pantoprazole · DIN 02307871 Manufacturer: Pharmascience Inc.; listing date 2008-08-28 Health Canada: Marketed since 2008-06-04 · brand PMS-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Pantoprazole: Formulary list price $0.2016/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2016 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79355 · Verify on the e-Formulary ↗ (DIN 02307871)

Source record

DIN 02307871: PMS-Pantoprazole Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id PMS Source form: Ent Tab; strength: 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2016; ministry $0.2016 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02307871 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79355

Interchangeable products

AG-Pantoprazole Sodium · DIN 02481588 · $0.2016 Apo-Pantoprazole · DIN 02292920 · $0.2016 Auro-Pantoprazole · DIN 02415208 · $0.2016 Bio-Pantoprazole · DIN 02445867 · $0.2016 Co Pantoprazole · DIN 02300486 · $0.2016 Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016 Jamp-Pantoprazole · DIN 02357054 · $0.2016 M-Pantoprazole · DIN 02467372 · $0.2016 Mar-Pantoprazole · DIN 02416565 · $0.2016 Mint-Pantoprazole · DIN 02417448 · $0.2016 NRA-Pantoprazole · DIN 02471825 · $0.2016 Pantoloc · DIN 02229453 · $0.2016 Pantoprazole · DIN 02370808 · $0.2016 Pantoprazole · DIN 02428180 · $0.2016 Pantoprazole · DIN 02431327 · $0.2016 Pantoprazole · DIN 02547368 · $0.2016 Ran-Pantoprazole · DIN 02305046 · $0.2016 Sandoz Pantoprazole · DIN 02301083 · $0.2016 Teva-Pantoprazole · DIN 02285487 · $0.2016

Shortage status: resolved shortage (ended 2020-06-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02307871

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Pantoprazole · DIN 02292912 · 20mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Pantoprazole · DIN 02292912 Manufacturer: Apotex Inc.; listing date 2008-06-27 Health Canada: Marketed since 2008-03-05 · brand APO-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77826 · Verify on the e-Formulary ↗ (DIN 02292912)

Source record

DIN 02292912: Apo-Pantoprazole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id APX Source form: Ent Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2750; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292912 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77826

Interchangeable products

Jamp Pantoprazole Sodium · DIN 02392615 · not recorded Jamp-Pantoprazole · DIN 02408414 · not recorded Mar-Pantoprazole · DIN 02416557 · not recorded Pantoloc · DIN 02241804 · not recorded Pantoprazole · DIN 02428172 · not recorded Pantoprazole · DIN 02536137 · not recorded Ran-Pantoprazole · DIN 02305038 · not recorded Sandoz Pantoprazole · DIN 02301075 · not recorded Teva-Pantoprazole · DIN 02285479 · not recorded

Shortage status: resolved shortage (ended 2025-02-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292912

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Pantoprazole Sodium · DIN 02392615 · 20mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Jamp Pantoprazole Sodium · DIN 02392615 Manufacturer: Jamp Pharma Corporation; listing date 2021-11-30 Health Canada: Marketed since 2021-11-26 · brand JAMP PANTOPRAZOLE SODIUM · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 20 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87787 · Verify on the e-Formulary ↗ (DIN 02392615)

Source record

DIN 02392615: Jamp Pantoprazole Sodium Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id JPC Source form: Ent Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2750; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02392615 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87787

Interchangeable products

Apo-Pantoprazole · DIN 02292912 · not recorded Jamp-Pantoprazole · DIN 02408414 · not recorded Mar-Pantoprazole · DIN 02416557 · not recorded Pantoloc · DIN 02241804 · not recorded Pantoprazole · DIN 02428172 · not recorded Pantoprazole · DIN 02536137 · not recorded Ran-Pantoprazole · DIN 02305038 · not recorded Sandoz Pantoprazole · DIN 02301075 · not recorded Teva-Pantoprazole · DIN 02285479 · not recorded

Shortage status: resolved shortage (ended 2025-08-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392615

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pantoloc · DIN 02241804 · 20mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: RxHelp ONE lists Pantoloc (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Pantoloc · DIN 02241804 Manufacturer: Nycomed Canada Inc.; listing date 2008-06-27 Health Canada: Marketed since 2013-01-09 · brand PANTOLOC · ATC A02BC02 PANTOPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20 MG · company Takeda canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Pantoloc: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65469 · Verify on the e-Formulary ↗ (DIN 02241804)

Source record

DIN 02241804: Pantoloc Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id NYC Source form: Ent Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241804 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65469

Interchangeable products

Apo-Pantoprazole · DIN 02292912 · not recorded Jamp Pantoprazole Sodium · DIN 02392615 · not recorded Jamp-Pantoprazole · DIN 02408414 · not recorded Mar-Pantoprazole · DIN 02416557 · not recorded Pantoprazole · DIN 02428172 · not recorded Pantoprazole · DIN 02536137 · not recorded Ran-Pantoprazole · DIN 02305038 · not recorded Sandoz Pantoprazole · DIN 02301075 · not recorded Teva-Pantoprazole · DIN 02285479 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241804

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pantoprazole · DIN 02428172 · 20mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Pantoprazole · DIN 02428172 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2024-03-21 · brand PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91265 · Verify on the e-Formulary ↗ (DIN 02428172)

Source record

DIN 02428172: Pantoprazole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id SIV Source form: Ent Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2750; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428172 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91265

Interchangeable products

Apo-Pantoprazole · DIN 02292912 · not recorded Jamp Pantoprazole Sodium · DIN 02392615 · not recorded Jamp-Pantoprazole · DIN 02408414 · not recorded Mar-Pantoprazole · DIN 02416557 · not recorded Pantoloc · DIN 02241804 · not recorded Pantoprazole · DIN 02536137 · not recorded Ran-Pantoprazole · DIN 02305038 · not recorded Sandoz Pantoprazole · DIN 02301075 · not recorded Teva-Pantoprazole · DIN 02285479 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428172

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pantoprazole · DIN 02536137 · 20mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Pantoprazole · DIN 02536137 Manufacturer: Sanis Health Inc.; listing date 2024-01-31 Health Canada: Marketed since 2023-11-17 · brand PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 20 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102493 · Verify on the e-Formulary ↗ (DIN 02536137)

Source record

DIN 02536137: Pantoprazole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id SAI Source form: Ent Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2750; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536137 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102493

Interchangeable products

Apo-Pantoprazole · DIN 02292912 · not recorded Jamp Pantoprazole Sodium · DIN 02392615 · not recorded Jamp-Pantoprazole · DIN 02408414 · not recorded Mar-Pantoprazole · DIN 02416557 · not recorded Pantoloc · DIN 02241804 · not recorded Pantoprazole · DIN 02428172 · not recorded Ran-Pantoprazole · DIN 02305038 · not recorded Sandoz Pantoprazole · DIN 02301075 · not recorded Teva-Pantoprazole · DIN 02285479 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02536137

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Pantoprazole · DIN 02301075 · 20mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Sandoz Pantoprazole · DIN 02301075 Manufacturer: Sandoz Canada Inc.; listing date 2008-11-04 Health Canada: Marketed since 2008-06-03 · brand SANDOZ PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 20 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78642 · Verify on the e-Formulary ↗ (DIN 02301075)

Source record

DIN 02301075: Sandoz Pantoprazole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id SDZ Source form: Ent Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2750; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02301075 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78642

Interchangeable products

Apo-Pantoprazole · DIN 02292912 · not recorded Jamp Pantoprazole Sodium · DIN 02392615 · not recorded Jamp-Pantoprazole · DIN 02408414 · not recorded Mar-Pantoprazole · DIN 02416557 · not recorded Pantoloc · DIN 02241804 · not recorded Pantoprazole · DIN 02428172 · not recorded Pantoprazole · DIN 02536137 · not recorded Ran-Pantoprazole · DIN 02305038 · not recorded Teva-Pantoprazole · DIN 02285479 · not recorded

Shortage status: resolved shortage (ended 2026-06-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02301075

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Pantoprazole · DIN 02285479 · 20mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Pantoprazole · DIN 02285479 Manufacturer: Teva Canada Limited; listing date 2008-08-28 Health Canada: Marketed since 2023-03-22 · brand TEVA-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 20 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77096 · Verify on the e-Formulary ↗ (DIN 02285479)

Source record

DIN 02285479: Teva-Pantoprazole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id TEV Source form: Ent Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2750; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02285479 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77096

Interchangeable products

Apo-Pantoprazole · DIN 02292912 · not recorded Jamp Pantoprazole Sodium · DIN 02392615 · not recorded Jamp-Pantoprazole · DIN 02408414 · not recorded Mar-Pantoprazole · DIN 02416557 · not recorded Pantoloc · DIN 02241804 · not recorded Pantoprazole · DIN 02428172 · not recorded Pantoprazole · DIN 02536137 · not recorded Ran-Pantoprazole · DIN 02305038 · not recorded Sandoz Pantoprazole · DIN 02301075 · not recorded

Shortage status: active shortage (reported 2024-03-06, last updated 2024-03-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285479

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PANTOPRAZOLE MAGNESIUM

Mylan-Pantoprazole T · DIN 02408570 · 40mg · Ent Coated tablet

Pantoprazole T · DIN 02466147 · 40mg · Ent Coated tablet

Pantoprazole T · DIN 02519534 · 40mg · Ent Coated tablet

Tecta · DIN 02267233 · 40mg · Ent Coated tablet

Teva-Pantoprazole Magnesium · DIN 02440628 · 40mg · Ent Coated tablet

Pantoprazole Magnesium · DIN 02441853 · 40mg · Ent Coated tablet

PANTOPRAZOLE SODIUM

AG-Pantoprazole Sodium · DIN 02481588 · 40mg · enteric-coated tablet

Apo-Pantoprazole · DIN 02292920 · 40mg · enteric-coated tablet

Auro-Pantoprazole · DIN 02415208 · 40mg · enteric-coated tablet

Bio-Pantoprazole · DIN 02445867 · 40mg · enteric-coated tablet

Jamp Pantoprazole Sodium · DIN 02392623 · 40mg · enteric-coated tablet

Jamp-Pantoprazole · DIN 02357054 · 40mg · enteric-coated tablet

M-Pantoprazole · DIN 02467372 · 40mg · enteric-coated tablet

Mar-Pantoprazole · DIN 02416565 · 40mg · enteric-coated tablet

Mint-Pantoprazole · DIN 02417448 · 40mg · enteric-coated tablet

NRA-Pantoprazole · DIN 02471825 · 40mg · enteric-coated tablet

PMS-Pantoprazole · DIN 02307871 · 40mg · enteric-coated tablet

Apo-Pantoprazole · DIN 02292912 · 20mg · enteric-coated tablet

Jamp Pantoprazole Sodium · DIN 02392615 · 20mg · enteric-coated tablet

Pantoloc · DIN 02241804 · 20mg · enteric-coated tablet

Pantoprazole · DIN 02428172 · 20mg · enteric-coated tablet

Pantoprazole · DIN 02536137 · 20mg · enteric-coated tablet

Sandoz Pantoprazole · DIN 02301075 · 20mg · enteric-coated tablet

Teva-Pantoprazole · DIN 02285479 · 20mg · enteric-coated tablet

Matched class: 56:40 Miscellaneous G.I. Drugs

Availability

Other review policies